Tumour infiltrating lymphocyte (TIL) therapy is here to stay...but toxicity may be the real bottleneck.
Most of it is not the TILs - itโs everything around them. We unpack this in our latest review.
Available #OpenAccess - ๐ ๐๐ฎ๐ฎ๐ถ๐ฏ๐ฐ๐๐ฉ๐ฆ๐ณ ๐๐ข๐ฏ๐ค๐ฆ๐ณ @sitcancer.bsky.social๐
๐ jitc.bmj.com/content/14/4...
